{
    "nct_id": "NCT04068597",
    "official_title": "An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 As Monotherapy and in Combination in Patients with Advanced Haematological Malignancies.",
    "inclusion_criteria": "* Provision of consent\n* ECOG performance status 0-2\n* Patients with confirmed (per standard disease specific diagnostic criteria), relapsed or refractory haematological malignancies (NHL, MM and AML)\n* Must have previously received standard therapy\n* Adequate organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Intervention with any chemotherapy, investigational agents or other anti-cancer drugs within 14 days or 5 half-lives of the first dose\n* Major surgical procedure or significant traumatic injury within 4 weeks of the first dose of study treatment\n* Strong inhibitors of CYP3A4 or CYP3A4 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment\n* Strong inducers of CYP3A4 within 4 weeks of the first dose of study treatment\n* Patients should discontinue statins prior to starting study treatment\n* CYP2C8 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment\n* Any unresolved reversible toxicities from prior therapy >CTCAE grade 1 at the time of starting study treatment (except alopecia and grade 2 neuropathy)\n* Any evidence of severe or uncontrolled systemic diseases\n* Any known uncontrolled inter-current illness\n* QTcF prolongation (> 480 msec)",
    "miscellaneous_criteria": ""
}